Aged-care residents will be among the first to receive the Pfizer vaccine when the rollout begins next week. For some, the process of consenting to the vaccine could raise ethical questions.
The synthesising of the mRNA for the Pfizer/BioNTech vaccine taking place at a facility in Marburg, Germany.
BioNTech/EPA-EFE
The Oxford/AstraZeneca vaccine is the latest to struggle against the South African variant in trials, while in Israel vaccines may be beginning to have an effect.
We've gone from a novel virus to several COVID-19 vaccines in less than a year. Here's what we've learned from earlier vaccines to allow this to happen.
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given could get around this.
Vaccine vials are being carefully stored ahead of being used, to make sure as little goes to waste as possible.
EPA-EFE
History tells us that mass vaccination campaigns are usually messy, while elsewhere, lower-income countries are turning to China, Russia and India for vaccines.
A coronavirus patient arrives at the Royal London Hospital in early January.
Yui Mok/PA Wire
Peter Martin, Crawford School of Public Policy, Australian National University
All sorts of transactions are "two-way value exchanges" in which it isn't clear in which direction the money should flow. The proposed media bargaining code is one of them.
As vaccination begins to take effect, what we'll be able to do will change – but the transformation will be slow.
Workers prepare to ship the Pfizer COVID-19 vaccine from the company’s manufacturing plant in Kalamazoo, Michigan.
Morry Gash/Pool/AFP via Getty Images
As the coronavirus rages, a vaccine finally is available for certain groups of people and will soon be ready for other groups. But there are plenty of questions. A doctor answers five here.